Molecular Health and Gen Era Diagnostics agree to collaborate in the field of precision oncology in Turkey

Molecular Health and Gen Era Diagnostics agree to collaborate in the field of precision oncology in Turkey

Heidelberg, 19. October 2021 – Molecular Health and the life science company Gen Era Diagnostics have signed a collaboration agreement to optimize the personalized treatment of patients with cancer. For this purpose, Gen Era will provide the MH Guide software platform to twenty laboratories in Turkey to use in the interpretation of tumor data.

“We are pleased to have Molecular Health on board in the near future as an experienced partner in precision medicine. With MH Guide, we can analyze and interpret molecular genetic data even faster and more comprehensively. This is an important addition to our service and product portfolio,” explains Damla Bozkulak, Head of Marketing and Business Development at Gen Era Diagnostics.

Gen Era Diagnostics is one of the leading product and service providers in the field of molecular diagnostics in Turkey. Founded in 2013, the company supports scientists, clinicians, and laboratories in the investigation of diseases and the treatment of patients. Gen Era’s offering includes solutions and services for molecular diagnostics in the fields of oncology, cardiology, and metabolic diseases, among others. In addition, the company offers services for the life sciences, including genomics, proteomics, and cell analyses.

“With MH Guide, doctors can manage the flood of data from molecular genetic testing and translate it into targeted therapy recommendations. We value the trust that Gen Era Diagnostics has placed in our technology and are convinced that patients in Turkey will benefit from it,” explains Thomas Holtrup, Senior Vice President, Head of Sales & Business Development, EMEA, at Molecular Health.

MH Guide is an analysis software for interpreting molecular data from cancer patients. It summarizes in a report the relevant genetic changes of a tumor that can be specifically addressed in individual patients either therapeutically or in clinical trials. In this way, treatment options can be expanded, especially for patients with metastatic disease.

Press contact:
Thomas König
Molecular Health
Thomas.Koenig@molecularhealth.com
Phone: +49 (0)6221-43512280

About Molecular Health:

Molecular Health is an international biotech IT company based in Heidelberg, Germany, that has been developing innovative software in the areas of in silico and precision medicine since 2004. Molecular Health’s solutions make it possible to transform large amounts of data into evidence-based, medically relevant decision support. They are used where precision medical patient care or efficient drug development requires increasingly complex data interpretations. At Molecular Health, specialists from the fields of medicine, data science, biology and bioinformatics, and software development are working to make Big Data useful for healthcare. The result is intuitive analysis applications that are individually tailored to different healthcare requirements. Molecular Health is a portfolio company of dievini Hopp Biotech holding GmbH & Co. KG.

Read more on www.molecularhealth.com

About Gen Era Diagnostics:

Gen Era Diagnostics is a biotech company founded in 2013. It is one of the leading institutions in the fields of molecular diagnostics and life science research in Turkey. With its service and product portfolio, Gen Era Diagnostics supports scientists, clinics and laboratories in the research, diagnosis and treatment of diseases. This includes oncological indications, cardiology, hematology and rare genetic diseases. In addition, Gen Era supports research projects in the fields of genomics, proteomics and cell analysis and offers bioinformatics services for scientific institutions.

More information at  Gen Era Diagnostik

Download pdf

MH Guide 5.0: Software for therapy planning in precision oncology, now available with a comprehensive update

MH Guide 5.0: Software for therapy planning in precision oncology, now available with a comprehensive update

Heidelberg, September 30, 2021. Molecular Health has launched the latest version of its analysis software MH Guide. This software, which is used by pathology laboratories and molecular tumor boards, now has improved search capabilities to identify patient- relevant clinical studies. With the VCF Adapter Suite, Molecular Health also offers a conversion tool to easily integrate data from the most common NGS sequencing systems.

The current version of MH Guide contains an optimized search and filter function for identifying relevant clinical studies. This allows more cancer patients to access studies that are suitable for them.

The VCF Adapter Suite was introduced alongside MH Guide 5.0. This conversion tool enables a simple connection to common NGS analysis systems. Currently, the following data can be converted into an MH Guide-compatible format:

• Illumina (TSO500, TST170, AmpliSeq)
• ArcherDX
• Qiagen
• Thermo Fisher Oncomine
• AmoyDx

This facilitates individual conversions and supports integration into fully automated processes.

“Many molecular pathology laboratories are now using our software for patients, who can benefit from targeted therapy or participation in a clinical trial based on the comprehensive analysis of their tumor genome,” explains PD Dr. Christian Meisel, Chief Medical Officer of Molecular Health. “This means that the treatment spectrum can be expanded and affected people can be given options,” Meisel continues.

“We are continuously working on improvements to our software and will continue to accommodate the use requirements of molecular tumor boards in further updates of MH Guide. Our goal is to provide the best possible information for evidence-based therapy decisions at all times,” explains Dr. Matthias Kopf, Head of Product Management at Molecular Health.

MH Guide is a browser-based software that is used in therapy planning for cancer patients. The software enables the automatic analysis of molecular data obtained using Next Generation Sequencing (NGS), and provides treating physicians with an evidence-based report for personalized therapy approaches. This report contains information on potentially effective targeted and immuno-oncological therapies and on ongoing clinical studies for which the patient is eligible. With the current software update (MH Guide 5.0), Molecular Health has made an improved version of the application available since September 1, 2021.

MH Guide is a proprietary technology from Molecular Health, an internationally active biotech IT company in Heidelberg, Germany. The software compares sequence data from molecular testing with information from one of the world’s largest and growing knowledge platforms (Dataome). Thus, the tool enables molecular pathologists and practitioners to keep pace with rapidly expanding medical knowledge and use insights for the treatment of their patients. 

Users can access the current version of MH Guide via https://analysis.mh.guide. Interested parties can obtain further information on the customerservice@molecularhealth.com.

Press contact:
Thomas König
Molecular Health
Thomas.Koenig@molecularhealth.com
Phone: +49 (0)6221-43512280

About Molecular Health:

Molecular Health is an international biotech IT company based in Heidelberg, Germany, that has been developing innovative software in the areas of in silico and precision medicine since 2004. Molecular Health’s solutions make it possible to transform large amounts of data into evidence-based, medically relevant decision support. They are used where precision medical patient care or efficient drug development requires increasingly complex data interpretations. At Molecular Health, specialists from the fields of medicine, data science, biology and bioinformatics, and software development are working to make Big Data useful for healthcare. The result is intuitive analysis applications that are individually tailored to different healthcare requirements. Molecular Health is a portfolio company of dievini Hopp Biotech holding GmbH & Co. KG.

Read more on www.molecularhealth.com

Download pdf

Molecular Health and Korean EONE-Diagnomics Genome Center (EDGC) join forces in liquid biopsy-based precision medicine

Heidelberg/Incheon, 15. September 2021. Molecular Health GmbH will collaborate with EONE-Diagnomics Genome Center Co. Ltd. (EDGC) to help its healthcare provider customers identify personalized treatment options for cancer patients. The collaboration is intended to establish leadership in the fast-growing precision medicine market for liquid biopsy. Therefore, the two partners combine two major proprietary technologies, Molecular Health’s MH Guide and EDGC’s ONCOCATCH-CDxTM. This allows comprehensive genomic tumor profiling to guide treatment in solid tumors.

“The cooperation between Molecular Health and EDGC connects two well-established players in the field of precision medicine and forms an alliance that has the potential to significantly improve diagnosis and tailored treatment of cancer patients”, says Stephan Hettich, SVP, Head of Sales & Business Development, APAC with Molecular Health. “We are very happy to have found a strong and experienced partner like EDGC to capture the Asian market together.”

EDGC is an international joint venture based in South Korea that develops leading-edge technology for genome analysis and precision as well as personalized medicine. With ONCOCATCH-CDx the research and development company developed a unique non-invasive biopsy for early diagnosis, companion diagnostics and monitoring of all-stage cancer. The test analyses circulating tumor DNA (ctDNA), which is released from cancer cells into the bloodstream, through next-generation sequencing technology and state-of-the-art in-house bioinformatics. This provides the basis for personalized medicine prescription and helps doctors and patients in the decision-making. The global life science journal GenomeWeb labeled ONCOCATCH as ‘one of the world’s best-advanced technologies for early cancer diagnosis.

As part of the cooperation, EDGC aims to utilize Molecular Health’s MH Guide, analysis software that supports oncologists and molecular pathologists in the interpretation of large molecular datasets. Independent of the sequencing technology used, MH Guide can make complex datasets readable, and automatically identify genetic variants that are relevant for the treatment of cancer patients.

“When combining MH Guide, including 28.000 gene variant – drug relations, with EDGC’s companion diagnostics service ONCOCATCH-CDx, qualitative comprehensive genomic profiling results can be provided to guide treatment in solid tumors,” Jeong Yoo-seok, EDGC Global Business Department Team Leader, summarizes the collaboration. “We are looking forward to our partnership with Molecular Health to further establish our leading positions in the upcoming precision medicine market for liquid biopsy”, he adds.

Please note
On 13th October 2021, EGDC and Molecular Health will be hosting a joint a webinar to give further details on the collaboration and the future joint activities. Partners may register by contacting yubinakim@edgc.com.

Press contact:
Thomas König
Molecular Health
Thomas.Koenig@molecularhealth.com
Phone: +49 (0)6221-43512280

Kim Seung-Gyun
EONE-Diagnomics Genome Center
seongyun.kim@edgc.com
Tel.: +82 32713-2190

About Molecular Health:

Molecular Health is an international biotech IT company based in Heidelberg, Germany, that has been developing innovative software in the areas of in silico and precision medicine since 2004. Molecular Health’s solutions make it possible to transform large amounts of data into evidence-based, medically relevant decision support. They are used where precision medical patient care or efficient drug development requires increasingly complex data interpretations. At Molecular Health, specialists from the fields of medicine, data science, biology and bioinformatics, and software development are working to make Big Data useful for healthcare. The result is intuitive analysis applications that are individually tailored to different healthcare requirements. Molecular Health is a portfolio company of dievini Hopp Biotech holding GmbH & Co. KG.

Read more on www.molecularhealth.com

About EONE-Diagnomics Genome Center:

EDGC is the international joint venture established in 2013 between EONE Laboratories and Diagnomics. EDGC has developed leading-edge technology for genome analysis through constant research and development and has established a business network to expand its influence on the global market. Because of that, EDGC diagnoses various diseases over the entire life cycle and provides clinical solution for precision and personalized medicine. As the global leader of genome business, EDGC has worked on global projects with the most influential BT and IT companies in the world such as Illumina and Microsoft.

Read more on www.edgc.com

Download pdf

Molecular Health and Universitätsmedizin Essen [Essen University Hospital] launch collaborative project to improve care for COVID-19 patients

Essen/Heidelberg, August 9, 2021. On August 1, 2021, the IT biotech company Molecular Health (MH) and Universitätsklinikum Essen kicked off a collaborative project funded by the BMG (Bundesministerium für Gesundheit [German Federal Ministry of Health]) to provide holistic and evidence-based care for COVID-19 patients. Using the MH Corona Explorer, a deeper understanding of the disease will be generated, linking the molecular basis to the clinical course of the disease. The goal is to enable innovative approaches to the diagnosis and treatment of COVID-19 patients and thus improve patient care.

The COVID-19 pandemic has crippled the world since 2020, with more than 190 million infections and more than 4 million deaths now reported. However, the state of knowledge about the disease is still insufficient, especially in terms of understanding COVID-19 disease at the molecular level in relation to a wide variety of clinical manifestations and symptoms. However, this understanding is critical to optimize diagnosis and treatment.

“To close this gap, we at Molecular Health have developed an enhanced COVID-19 disease model (“MH Corona Explorer”) based on our curated knowledge base (“DATAOME”) that links and represents the different symptoms of the disease with their molecular pathways. We are delighted to be able to implement this innovative collaborative project together with the experts and clinical expertise of Universitätsmedizin Essen,” said Dr. Anna Laib, Head of Medical Affairs and project leader of the Molecular Health collaboration at the kick-off meeting on August 3, 2021 at Uniklinikum Essen.

MH Corona Explorer’s in-silico approach as a browser-based application draws on biomedical knowledge published worldwide within the Molecular Health database. Using this digital model, the various clinical molecular features of COVID-19 are identified. This approach explains the long-term course of the disease, in addition to the variety of symptoms, while generating guidance for new treatment approaches.

To systematically advance the decoding of the disease, clinical data from up to 2,000 COVID-19 patients treated at the Universitätsmedizin Essen will be analyzed and linked to the digital model to identify new drug targets and biomarkers. Findings from the collaborative project, which is scheduled to run for approximately one year, may also provide defined predictors of progression to severe disease or even long-term disease due to COVID-19 (“long Covid”). “This is not just about funding research, but about funding the future of medicine – with this perspective, the joint project between the Universitätsmedizin Essen and Molecular Health offers an investment in the further development of healthcare,” commented Nick Schneider, Head of Division at the Bundesministerium für Gesundheit.

The relevance of the project is underlined by PD Dr. Adalbert Krawczyk, laboratory manager of infectiology and project manager on the part of the Universitätsmedizin Essen: “Not only do we have an extensive clinical dataset of COVID-19 patients, but we also have a large biospecimen set to control for potential biomarkers – we would like to capture these for early and reliable risk assessment of COVID-19 sufferers to use predictively or prognostically.”

Prof. Dr. med. Oliver Witzke, Director of the Klinik für Infektiologie [Clinic for Infectious Diseases] and the Westdeutsches Zentrum für Infektiologie [West German Center for Infectious Diseases] and project leader on the part of the Universitätsklinikums Essen, looks forward to the joint project with excitement: “Through this collaboration, our clinical knowledge from the field, along with Molecular Health’s in-depth COVID-19 disease model, can be made directly useful to physicians in patient care. In the future, we hope to be able to keep our finger on the pulse of the pandemic by networking information on new virus variants and correspondingly changing courses of disease: Emerging adaptable treatment strategies could serve as a key component of care, contributing to the management of this pandemic.” Initial results of the model project will be presented at a workshop this coming November.

Press contact:
Thomas König
Molecular Health
Thomas.Koenig@molecularhealth.com
Phone: +49 (0)6221-43512280

About Molecular Health:
Molecular Health is an international biotech IT company based in Heidelberg, Germany, that has been developing innovative software in the areas of in silico and precision medicine since 2004. Molecular Health’s solutions make it possible to transform large amounts of data into evidence-based, medically relevant decision support. They are used where precision medical patient care or efficient drug development requires increasingly complex data interpretations. At Molecular Health, specialists from the fields of medicine, data science, biology and bioinformatics, and software development are working to make Big Data useful for healthcare. The result is intuitive analysis applications that are individually tailored to different healthcare requirements. Molecular Health is a portfolio company of dievini Hopp Biotech holding GmbH & Co. KG.

Download pdf

Konyang University Hospital in South Korea relies on MH Guide for personalized cancer medicine

Konyang University Hospital in South Korea relies on MH Guide for personalized cancer medicine

Heidelberg/Daejeong, July 16, 2021 – Konyang University Hospital in Daejeong, South Korea, will rely on MH Guide in the personalized treatment of its cancer patients. This is the result of an agreement between the hospital and Molecular Health. It makes Konyang University Hospital the first facility in South Korea to use MH Guide. “Precision medicine in cancer care enables personalized treatment through comprehensive analysis of genes, clinical information and drugs. With our NGS system and MH Guide, we have a complete precision medicine ecosystem that will enable us to provide world-class cancer care,” said Yoon Dae-seong, Director of the Cancer Center at Konyang University Hospital.

MH Guide is an analysis software that helps molecular pathologists and oncologists interpret NGS data and make treatment decisions. The software automatically detects relevant gene variants from molecular information and identifies treatment options based on the molecular profile and ongoing trials that may be relevant to the patient. To do this, MH Guide matches molecular patient data with data derived from one of the largest growing and Molecular Health-owned knowledge platforms (Dataome). This makes MH Guide an evidence-based decision support tool that enables physicians and molecular pathologists to keep pace with the rapidly growing stock of medical knowledge and make it actionable in treating their patients.

“We are very pleased to collaborate with Konyang University Hospital. We are convinced that with MH Guide we can make an important contribution to the personalized care for Korean patients,” said Stephan Hettich, SVP, Head of Sales & Business Development, APAC, at Molecular Health. 

About Molecular Health:

Molecular Health (MH) is an internationally operating biotech IT company located in Heidelberg, Germany, which has been developing innovative software in the fields of in silico and precision medicine since 2004. The solutions by MH enable large quantities of data to be transformed into evidence-based, medically relevant decision-making tools. They are used where patient care with precision medicine or efficient drug development require increasingly complex interpretation of data. MH specialists from the fields of medicine, data science, biology and bioinformatics as well as software development are working on transforming big data into a useful tool for healthcare. The result is intuitive analysis applications which are individually tailored to various requirements in healthcare. MH is an investment management company of dievini Hopp Biotech holding GmbH & Co. KG.

Additional information can be found at www.molecularhealth.com

About Konyang University Hospital:

Established in February 2000, Konyang University Hospital (KYUH) is one of the leading hospitals in cancer care in Korea with an 813-bed-capacity. The hospital consists of 32 departments, 14 specialized medical centers and 16 clinics. The cancer center of the hospital is comprised of 12 specialized teams such as the gastric cancer, the lung cancer, or the liver cancer team. The hospital is equipped with the latest cancer treatment facilities such as RapidArc™, Cyclotron, Robotic CyberKnife and Da Vinci surgery robots. KYUH treats more than 500 cancer patients per year. It employs 120 medical doctors, and three of them specialize in oncology.

Website: www.kyuh.ac.kr   

 

PDF Download

Molecular Health and FALCO biosystems…

Heidelberg, Germany, March 02, 2021 – Molecular Health GmbH announced today that it has entered into an agreement with Kyoto-based FALCO biosystems Ltd. under which FALCO biosystems will use the products MH Guide/BRCA and MH Guide/Mendel to evaluate inherited genetic variants of BRCA1/2 and other heritable cancer-associated genes.

Inherited genetic variants can predispose an individual to cancer. Hereditary Breast and Ovarian Cancer (HBOC) Syndrome, for example, is caused by pathogenic mutations in distinct genes such as BRCA1/2, MLH1, MSH6, PMS2, respectively. Therefore, testing BRCA1/2 genes and other heritable cancer-associated genes is becoming increasingly important: both to evaluate the affected patient’s individual risk of developing cancer1,2, and as a predictive biomarker and companion diagnostic test for certain drugs3. Whereas MH Guide/BRCA detects variants in HBOC-associated genes, MH Guide/Mendel can analyze large gene panels as well as whole- exome or whole-genome data, so that many different hereditary diseases can be identified at once.

“With this collaboration in place, Japanese patients will benefit from state-of-the-art genetic identification of inherited diseases like Hereditary Breast and Ovarian Cancer and many other diseases. This will allow sooner diagnosis and potentially earlier therapeutic intervention”, said Christian Meisel, MD, PhD, Chief Medical Officer at Molecular Health.

Under the terms of this collaboration, FALCO biosystems will perform the next-generation sequencing (NGS) process and variant identification using blood samples provided by the patient. Molecular Health will then analyze the variant data using MH Guide/BRCA or MH Guide/Mendel. To accurately distinguish benign from pathogenic variants, MH uses an in-house proprietary database called MH Dataome, which integrates the Japanese reference genome ToMMo 3.5KJPNv2 (MAF ≥ 1%) for improved variant filtering and classification. Molecular Health gratefully acknowledges the contribution of Tohoku Medical Megabank.

Download pdf

CENTOGENE and Molecular Health Announce an Exclusive Collaboration With the Aim to Transform the Development of Orphan Drugs

Newsroom

All news

CENTOGENE and Molecular Health Announce an Exclusive Collaboration With the Aim to Transform the Development of Orphan Drugs  

 

  • The combination of real-life data sets in rare diseases with innovative big data/artificial intelligence/novel scientific computational knowledge will transform biomedical research, product development, and therapy.
  • Real-life data and Innovative Bioinformatic Algorithms (RIBA project) will enable the creation of a powerful environment to accelerate, de-risk, and improve the development of new orphan drugs for many diseases and disease areas.
  • RIBA develops and offers data-/computing-driven solutions to guide the highest and most precise innovation for a new way of drug development in a modern biopharmaceutical environment.
  • The collaboration will start with Epilepsy as the first indication

Cambridge, MA, USA & Rostock/Berlin, Germany, and Heidelberg, Germany, July 20, 2020 (GLOBE NEWSWIRE) – Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, and Molecular Health, a leading company in the field of data and computing science for precision medicine, announced today that they will collaborate exclusively to initiate the Real-life data and Innovative Bioinformatic Algorithms (RIBA) project – starting with Epilepsy as the first indication. RIBA aims to foster a unique novel precision medicine environment to accelerate, de-risk, and improve the development of new orphan drugs based on the combination of large real-life data sets in rare disease with innovative big data, innovative artificial intelligence, as well as computational algorithms and expertise. Both companies are convinced that this strategy of merging real-life data with a global curated biomedical knowledge, as well as applying artificial intelligence and scientific computing will radically change and transform biomedical research, product development, and therapy. Additionally, it will offer data-/computing-driven solutions to guide the highest and most precise innovation for the new way of drug development in a modern biopharmaceutical environment.

 

Prof. Arndt Rolfs, CENTOGENE Chief Executive Officer, stated, “We are excited about this collaboration. Both companies have been analyzing the potential interaction for an extended period of time and are deeply convinced that now is the right time to start an exclusive cooperation focusing on rare genetic diseases. The complementary expertise and knowledge of both companies will allow us to reduce the time to develop a new orphan drug by combining of real-life data and innovative computational biomedical expertise. CentoMD®, one of the world’s largest rare disease data repositories, allows us to take advantage of the high quality of the real-life data from a global cohort of more than 500,000 consented patients. The extraordinary expertise of Molecular Health will not only speed up the identification of new targets in rare disease, but also allow us to de-risk and accelerate the development of new orphan drugs.”

 

“By starting this exciting collaboration between our companies, we are initiating and building a unique novel model of personalized healthcare. The combination of both companies’ data and expertise will ultimately transform modern drug development and therapy. It will allow for the development of better drugs with higher specificity and safety, lower attrition rates in clinical studies, and a faster time to market to help patients with severe diseases worldwide through novel therapies,” said Dr. Friedrich von Bohlen, Molecular Health Chief Executive Officer. “Together with CENTOGENE, Molecular Health´s deep scientific, medical, and computational expertise will lay the fundament for personalized healthcare options in rare diseases to fulfill the promise of precision medicine.”

 

The companies have agreed to start with Epilepsy as the first indication. Financial details were not disclosed.

Molecular Health announces collaboration with German private insurer HanseMerkur.

Newsroom

All news

Molecular Health announces collaboration with German private insurer HanseMerkur: Digitally supported cancer diagnostics improves tumor treatment

 

Hamburg / Heidelberg, October 16, 2019. The widespread disease of cancer has many manifestations and degrees of severity. Promising progress has been made by medicine in recent years with individualized (i.e. genetically adapted to the individual) medicine. Thanks to a cooperation with the Heidelberg-based company Molecular Health, the fully-insured customers of German private insurer HanseMerkur now also benefit from this for certain cancer types.

 

> Continue reading (in German)

 

Die Vereinbarung betrifft Vollversicherte mit der Diagnose einer wiederkehrenden Tumorerkrankung, z. B. einem wiederkehrenden Eierstock-, Eileiter- oder Bauchfellkrebs oder bei einer neuerlichen Tumorerkrankung im Kindes- und Jugendalter.

Die Analyse der Tumor-DNA und ihre anschließende Auswertung ermöglicht es Onkologen, eine optimal auf jeden einzelnen Patienten zugeschnittene Therapie auszuwählen, um die Erfolgsaussichten vor allem bei schweren Krankheitsverläufen zu erhöhen. So können z. B. bei Tumoren, die auf die Standardtherapien nicht ansprechen, oder bei wiederkehrenden Tumoren rasch neue Behandlungsmöglichkeiten erschlossen werden. Ermöglicht wird die erweiterte Diagnostik und Behandlung durch die Software MH Guide, die biologische, molekulare, klinische und pharmakologische Daten in Beziehung setzt – weltweit verfügbares Wissen über Tumorveränderungen und Therapien, auf das die behandelnden Ärzte zugreifen können.

 

Dr. Friedrich von Bohlen, CEO von Molecular Health, erklärt: „Wir freuen uns sehr über den Abschluss der ersten Kooperation mit einer privaten Versicherungsgruppe zu unserem Produkt MH Guide. Die HanseMerkur ist für uns ein idealer Partner, um einer breiten Gruppe an Patienten den Zugang zur onkologischen Präzisionsdiagnostik und
somit den bestmöglichen Therapieoptionen zu eröffnen. Wir sind fest davon überzeugt, dass MH Guide die behandelnden Ärzte gut darin unterstützen wird, informierte, evidenzbasierte und personalisierte Behandlungsentscheidungen für ihre Patienten zu treffen.“

Holger Ehses, Vorstandsmitglied der HanseMerkur Krankenversicherung AG in Hamburg, ergänzt: „Durch den Zugang zu diesem innovativen Instrument der Präzisionsdiagnostik schaffen wir für unsere Versicherten erneut eine verbesserte Versorgung in der Krebsbehandlung. Genetische Analysen spielen in der modernen Krebs-Diagnostik eine zunehmend wichtige Rolle. Durch die Kooperation mit Molecular Health gehen wir einen wichtigen Schritt, unseren umfangreichen Leistungskatalog durch modernste qualitätsgesicherte Angebote zu ergänzen.“

 

Über Molecular Health

Molecular Health ist ein Unternehmen aus dem Bereich der computergestützten Präzisionsmedizin, das mit seinem Fokus auf Data Science und künstlicher Intelligenz die Entscheidungsfindung für Organisationen im Gesundheitssektor verbessert. Die Angebote des Unternehmens basieren auf der Erfassung, Organisation, Integration und Analyse großer Datenmengen aus Biomedizin und Arzneimittelforschung, die mit neuartigen Technologien wie künstlicher Intelligenz und maschinellem Lernen kombiniert werden. Dies erlaubt Ärzten und Patienten eine bessere Diagnose oder Therapieentscheidungen. Weitere Informationen unter www.molecularhealth.com.

 

Über die HanseMerkur

Die HanseMerkur ist mit einem Jahresumsatz von über 2 Mrd. Euro (2018) die einzige selbständige und konzernunabhängige Versicherungsgruppe am Finanzplatz Hamburg. Die Wurzeln des 144 Jahre alten Personenversicherers liegen in der Krankenversicherung, die bis heute die Hauptsparte des Unternehmens ist. Die HanseMerkur ist zudem Spezialist für den privaten Ergänzungsschutz gesetzlich Krankenversicherter und mit rund 1,2 Millionen Zusatzversicherten in diesem Segment einer der größten deutschen Anbieter. In der Privaten Krankenversicherung rangiert sie auf Platz 11 von 41 Anbietern. Darüber hinaus zählt die HanseMerkur zu den größten Unternehmen der touristischen Assekuranz in Deutschland. Weitere Informationen unter www.hansemerkur.de.

Molecular Health to present at upcoming congresses

Newsroom

All news

Molecular Health to present at upcoming congresses

 

  • Molecular Health will attend several upcoming conferences in Europe and the US
  • Leading experts from the Company to present on AI in drug repurposing and evidence-driven decision support in research and clinical care

Heidelberg – September 19, 2019 – Molecular Health, a leading company in the field of data science for precision medicine and specializing in the development of products and services leveraging its proprietary biomedicine technology platform Dataome, is due to participate in several upcoming conferences between September and December, 2019. Company executives will give talks and participate in panel discussions on the use of artificial intelligence in the medical sector. The Company will present its product MH Predict, which assesses the likelihood of success of clinical trials. Moreover, it can be used for in silico-driven validation to identify drugs that can potentially be repurposed to treat other conditions. Further, Molecular Health will discuss its strategies for content curation in database generation and maintenance. Information on MH Guide, the company’s product to support physicians in selecting the optimal treatment for patients with cancer, will be available at several conferences. In addition, Dr. Friedrich von Bohlen, CEO of Molecular Health will participate in a panel discussion on the fusion of medicine and artificial intelligence at ‘Wissenswerte’ in Bremen. Please see below for details on the presentations as well as conferences where Molecular Health will host booths and will be available to discuss the range of applications of Dataome.

Drug Repurposing and Clinical Trial Success Prediction

Talk: ”Novel Approach to Drug Repurposing by Mining Safety Data and AI-based Simulation of Clinical Trials”

Clinical observations have historically been one of the most prominent sources for drug repurposing hypotheses. Molecular Health has taken the FDA’s vast set of clinical safety reports, cleaned and mapped them to their knowledge base of drugs, targets and pathways, and leveraged the analytics of their software application MH Effect to rapidly identify drug candidates.

In this talk, Prof. Armin Schneider, MD, PhD, SVP Scientific & Medical Affairs Molecular Health, will present Molecular Health’s proprietary approach to identify repurposing candidates, presenting examples of repurposing projects in tuberculosis and neonatal health.

Furthermore, he will showcase an in silico feasibility assessment by simulating clinical trial success using Molecular Health’s AI-driven software MH Predict, to support valuation and planning of the repurposed drug’s development program.

Monday, September 23, 2019, 10:30 – 11:00 am

8th Annual Drug Repositioning and Repurposing Conference | Washington, DC | September 23-24, 2019

            Venue:           The Westin Arlington Gateway, 801 North Glebe Road, Arlington, VA 22203, USA

            Speaker:        Prof. Armin Schneider, MD, PhD, SVP Scientific & Medical Affairs Molecular Health

            Program:      https://www.drugrepositioningconference.com/index/agenda

Talk: Predict R&D success. With AI

Around 85% of potential drugs entering Phase I clinical trials are destined to fail[1]. With MH Predict, Molecular Health has recently launched an AI tool that can predict the probability of success of clinical trials. In this talk, Prof. Armin Schneider will introduce Molecular Health’s proprietary prediction software and will discuss its application in a range of different scenarios. MH Predict can be used in the design of clinical trials to optimize key parameters as well as to predict trial success. In addition to analyzing a company’s own trials, the evaluation of clinical trials of competitors is another use case. Portfolio management and asset search and evaluation can also profit from Molecular Health’s software. Finally, MH Predict is able to perform in silico-driven hypothesis assessments, evaluate drug combinations in silico to improve treatment strategies, and identify candidates for drug repurposing.

[1]           Smietana, Katarzyna & Siatkowski, Marcin & Møller, Martin. (2016). Trends in clinical success rates. Nature Reviews Drug Discovery. 15. 10.1038/nrd.2016.85.

 

Thursday, September 26, 2019, 9:00 am

European Business Development Conference 2019 | Heidelberg, Germany | September 25-26, 2019

            Venue:           Deutsches Krebsforschungszentrum (DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany

            Speaker:        Prof. Armin Schneider, MD, PhD, SVP Scientific & Medical Affairs Molecular Health

            Program:      https://www.biodeutschland.org/de/european-business-development-conference-2019.html

 

Wednesday, December 4, 2019, 3:30 pm

BioData World Congress 2019 | Basel, Switzerland | December 4-5, 2019

          The world’s leading congress for big data & AI in life science and healthcare

           Venue:           Basel Congress Center, Messeplatz 21, 4058 Basel, Switzerland

           Speaker:        Prof. Armin Schneider, MD, PhD, SVP Scientific & Medical Affairs Molecular Health

           Program:       https://www.terrapinn.com/conference/biodata/agenda.stm

           Booth:           Molecular Health is Silver Sponsor and exhibitor. Visit us at booth # 22

 

Digital Health and Database Content Development

Talk: “Digital Health – Wo Medizin und KI verschmelzen“
(”Digital Health – Where Medicine and AI Merge“)
During Germany’s most important conference for science journalism, Dr. Friedrich von Bohlen, CEO Molecular Health, will participate in a panel discussion on the role of artificial intelligence in today’s health landscape.

Tuesday, November 26, 2019, 10:45 am – 12:15 pm

Wissenswerte | Bremen, Germany | November 25-26, 2019

           Venue:           Congress Centrum Bremen, Borgward Saal, Theodor-Heuss-Allee 15, 28215 Bremen, Germany

           Panelist:        Dr. Friedrich von Bohlen, CEO Molecular Health

           Program:      https://wissenswerte-bremen.de/sessions/#rdv-calendar

 

Talk: “Evidence-driven decision support in research and clinical care –
Content development technology & strategy for ‘smart’ applications in regulated and exploratory medical environments”
Personalized genomic information and the large amount of research published in this field supports the entire value chain of medication: From pre-clinical research to clinical trials and eventually to treatment decisions made in the clinical practice. To support the seamless use of IT applications to deliver the right piece of information in response to a specific expert question, Molecular Health identified the need for – and set up –a canonical knowledge repository and reference system.

However, to be useful in an industrial setup, content engineering needs to balance manual data curation vs. automated content extraction, and data quality vs. data coverage. In the presentation, Molecular Health will therefore demonstrate the use of text-analytics AI and a collaborative data-curation platform in support of content production. Furthermore, commercial applications will be portrayed, ranging from a ‘medical device’ certified for evidence-based treatment decision support to an AI system to predict and analyze the likelihood of success of clinical trials.

Thursday, December 5, 2019, 12:00 – 12:20 pm

ConTech 2019 | London | December 5-6, 2019

           Venue:           Millenium Gloucester Hotel, 4-18 Harrington Gardens, South Kensington, London SW74LH, UK

           Speaker:        Dr. Mathias Goeschl, VP of Digital Content, Molecular Health
           https://contechlive.com/speakers/mathias-goeschl-molecular-health-gmbh/

           Program:      https://contechlive.com/event/contech-2019/

 

MH Guide

Molecular Health will host booths to present and discuss its genome-guided cancer treatment decision support software MH Guide at the industry exhibitions of the following conferences:

 

ESMO Congress 2019 | Barcelona, Spain | September 27 – October 01, 2019
             Translating science into better cancer patient care.

             Molecular Health is an exhibitor. Visit us at booth # 461, hall 3

 

AMP 2019 Annual Meeting & Expo | Baltimore, MD (USA) | November 7-9, 2019
             Premier gathering for molecular professionals.
             Molecular Health is exhibitor. Visit us at booth # 2323

 

 

About Molecular Health

Molecular Health is a data science-focused artificial intelligence computing company enabling and improving decision making in precision medicine for healthcare organizations. The company offerings are based on the capture, curation, integration, and analysis of large biomedical and drug data sets and combining them with novel artificial intelligence and machine learning (AI/ML) technologies. For more than a decade, the company has been developing Dataome, a unique high-quality curated, interoperable system that combines clinico-molecular and drug data with proprietary analytical processes. Dataome – stand alone or in combination with customer data – enables the unlocking of actionable intelligence at the molecular level to a) improve diagnosis and therapy decisions by physicians and patients; b) enrich and support better drug discovery, drug development, trial optimization, drug differentiation and positioning for pharma and healthcare organizations; and c) more accurately predict the likelihood of success and likelihood of approval of drug candidates in clinical development for better trial prioritization and resource and investment allocation.

For more information, visit www.molecularhealth.com.

 

Molecular Health GmbH

Thomas König

Head of Marketing & PR

thomas.koenig@molecularhealth.com

Media Relations

MC Services AG

Katja Arnold, Eva Bauer

molecularhealth@mc-services.eu

+49-89-210 228 0

https://www.molecularhealth.com

 

Molecular Health signs up HudsonAlpha Institute for Biotechnology as new US customer for MH Guide

Newsroom

All news

Molecular Health signs up HudsonAlpha Institute for Biotechnology as new US customer for MH Guide

 

Molecular Health signs up HudsonAlpha Institute for Biotechnology as new US customer for MH Guide

 

  • Molecular Health Guide (MH Guide) gains ground in important U.S. market
  • MH Guide easily translates complex genetic data to support intelligent personalized medical decisions

Heidelberg, Germany – May 31, 2019 – Molecular Health (MH), a leading company in the field of data science for precision medicine, today announced that the Company has signed up the HudsonAlpha Institute for Biotechnology (HudsonAlpha) as a new client for MH Guide. HudsonAlpha is a nonprofit institute dedicated to developing and applying scientific advances to health, agriculture, learning, and commercialization.

 

MH Guide enables smarter patient care decisions based on deeper and broader biomedical information: Molecular pathologists and human geneticists can interpret genetic data derived from different technologies, such as next-generation sequencing, and create clinical reports that include drug information and variant classifications in minutes – easily, confidently, and accurately. HudsonAlpha plans to use MH Guide to elucidate detailed information on mutations found in patient tumor samples.

 

Dr. Friedrich von Bohlen, Co-founder and CEO of Molecular Health, said: ”Molecular Health is increasing its footprint in the U.S. as we sign on important new clients for our products. We are delighted to welcome HudsonAlpha as a customer and look forward to contributing through MH Guide to the important work they are doing to advance science and healthcare.”

 

About MH Guide
MH Guide, the gold standard in genomic data processing and analysis, is a rich bioinformatics platform, allowing medical professionals to analyze variants in the context of a patient’s cancer disease or predisposition to support identification of the potentially most effective treatments or disease predispositions. Molecular Health integrates private and publicly available databases, peer-reviewed scientific literature, and genome studies to extract salient information categorized by gene variant, disease, indication, cancer pharmacogenetics, and other relevant clinical classifiers. The stringent quality process Molecular Health follows to annotate and create its medical content is what sets MH Guide apart. Clients retain ownership of all data at all stages of the analysis, including the analysis results, which can be provided in a variety of digital formats, and have access to all source evidence for the annotations provided by the system. MH Guide is the first software product approved as an IVD medical device by the EU and is currently eligible for reimbursement in the EU.